tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RGNX Stock Latest News

Regenxbio price target raised to $45 from $40 at Stifel
The FlyRegenxbio price target raised to $45 from $40 at Stifel
24h ago
RGNX
Regenxbio price target raised to $20 from $16 at Leerink
PremiumThe Fly
Regenxbio price target raised to $20 from $16 at Leerink
5d ago
RGNX
RegenXBio’s Strategic Positioning and Advancements Drive Buy Rating Amid Market Opportunities
PremiumRatings
RegenXBio’s Strategic Positioning and Advancements Drive Buy Rating Amid Market Opportunities
5d ago
RGNX
RegenXBio’s Gene Therapy Study for Hunter Syndrome: A Potential Game-Changer
PremiumCompany Announcements
RegenXBio’s Gene Therapy Study for Hunter Syndrome: A Potential Game-Changer
6d ago
RGNX
Regenxbio files $300M mixed securities shelf
PremiumThe Fly
Regenxbio files $300M mixed securities shelf
24d ago
RGNX
RegenXBio’s Strategic Manufacturing and Commercial Readiness Justifies Buy Rating and $34 Price Target
PremiumRatingsRegenXBio’s Strategic Manufacturing and Commercial Readiness Justifies Buy Rating and $34 Price Target
1M ago
RGNX
RegenXBio’s Strategic Manufacturing Edge and Market Position Justify Buy Rating
Premium
Ratings
RegenXBio’s Strategic Manufacturing Edge and Market Position Justify Buy Rating
1M ago
RGNX
RegenXBio Inc. Earnings Call: Positive Progress Amid Challenges
Premium
Company Announcements
RegenXBio Inc. Earnings Call: Positive Progress Amid Challenges
1M ago
RGNX
Regenxbio price target raised to $25 from $24 at Morgan Stanley
PremiumThe Fly
Regenxbio price target raised to $25 from $24 at Morgan Stanley
1M ago
RGNX
REGENXBIO Reports Q3 2025 Financial and Operational Progress
PremiumCompany Announcements
REGENXBIO Reports Q3 2025 Financial and Operational Progress
1M ago
RGNX
Regenxbio reports Q3 EPS ($1.20), consensus ($1.30)
PremiumThe Fly
Regenxbio reports Q3 EPS ($1.20), consensus ($1.30)
1M ago
RGNX
Regenxbio expects cash, equivalents to fund operations into early 2027
PremiumThe Fly
Regenxbio expects cash, equivalents to fund operations into early 2027
1M ago
RGNX
FDA’s ‘surprising’ uniQure reversal drags down Biohaven
PremiumThe FlyFDA’s ‘surprising’ uniQure reversal drags down Biohaven
2M ago
BHVN
QURE
RegenXBio’s Strong Position in Biotechnology Justifies Buy Rating Amid Gene Therapy Uncertainties
Premium
Ratings
RegenXBio’s Strong Position in Biotechnology Justifies Buy Rating Amid Gene Therapy Uncertainties
2M ago
RGNX
FDA’s uniQure reversal unlikely to impact Regenxbio’s programs, says Stifel
Premium
The Fly
FDA’s uniQure reversal unlikely to impact Regenxbio’s programs, says Stifel
2M ago
QURE
RGNX
Regenxbio completes enrollment in Duchenne trial, begins RGX-202 production
PremiumThe Fly
Regenxbio completes enrollment in Duchenne trial, begins RGX-202 production
2M ago
RGNX
RegenXBio’s RGX-202 Gene Therapy: A Promising Step for Duchenne Muscular Dystrophy
PremiumCompany Announcements
RegenXBio’s RGX-202 Gene Therapy: A Promising Step for Duchenne Muscular Dystrophy
2M ago
RGNX
RegenXBio’s RGX-202: Promising Long-term Study for Duchenne Muscular Dystrophy
PremiumCompany Announcements
RegenXBio’s RGX-202: Promising Long-term Study for Duchenne Muscular Dystrophy
2M ago
RGNX
RegenXBio’s New Study: A Step Forward in DMD Research
PremiumCompany Announcements
RegenXBio’s New Study: A Step Forward in DMD Research
2M ago
RGNX
Regenxbio completes enrollment in Atmosphere, Ascent pivotal studies
PremiumThe FlyRegenxbio completes enrollment in Atmosphere, Ascent pivotal studies
3M ago
RGNX
Promising Data and Regulatory Progress Bolster Buy Rating for RegenXBio’s RGX-121
Premium
Ratings
Promising Data and Regulatory Progress Bolster Buy Rating for RegenXBio’s RGX-121
3M ago
RGNX
Promising Data and Strategic Moves Position RegenXBio for Potential Success with RGX-121
Premium
Ratings
Promising Data and Strategic Moves Position RegenXBio for Potential Success with RGX-121
3M ago
RGNX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >